September 18, 2020

To
The Secretary
BSE Limited
Department of Corporate Services
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400 001
Scrip Code - 532523

To
The Secretary
National Stock Exchange of India Limited
Corporate Communication Department
Exchange Plaza, Bandra Kurla Complex
Mumbai – 400 050
Scrip Symbol- BIOCON

Dear Sir/Madam,


With reference to the captioned subject, please find enclosed Investor Presentation, presented at the Investor Meeting held on September 16, 2020.

The above information will also be available on the website of the Company at www.biocon.com.

Kindly take the above said information on record.

Thanking You,

Yours faithfully,

For Biocon Limited

Mayank Verma
Company Secretary and Compliance Officer

Encl: Investor Presentation
Certain statements in this release concerning our future growth prospects are forward-looking statements, which are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those contemplated in such forward-looking statements. Important factors that could cause actual results to differ materially from our expectations include, amongst others general economic and business conditions, our ability to successfully implement our strategy, our research and development efforts, our growth and expansion plans and technological changes, changes in the value of the Rupee and other currencies, changes in the Indian and international interest rates, change in laws and regulations that apply to the Indian and global biotechnology and pharmaceuticals industries, increasing competition in and the conditions of the biotechnology and pharmaceuticals industries, changes in political conditions and changes in the foreign exchange control regulations. Neither the company, nor its directors and any of the affiliates have any obligation to update or otherwise revise any statements reflecting circumstances arising after this date or to reflect the occurrence of underlying events, even if the underlying assumptions do not come to fruition.
**Healthcare is a ‘Human Right’**

~2B people, a third of the world’s population across developed and LMIC countries, lack access to essential medicines

<table>
<thead>
<tr>
<th>Estimated Breast Cancer treatment cost</th>
<th>Time equivalent based on avg. annual wages*</th>
</tr>
</thead>
<tbody>
<tr>
<td>$18.5k</td>
<td>~10 years</td>
</tr>
<tr>
<td>$33.9k</td>
<td>~10 years</td>
</tr>
<tr>
<td>$71.7k</td>
<td>~1.7 years</td>
</tr>
</tbody>
</table>

*Not disposable income

Affordable Innovative Therapies

Expected to be worsened post COVID-19 pandemic
Platform built on 40+ years of strong heritage

Building an ecosystem where people are willing and able to continuously innovate

- ‘Pure Play’ Biosimilars Company
- Fully integrated – lab to market
- Global Footprint
- Disruptive collaborations

*rProteins refers to Recombinant Proteins
Ambition to transform global healthcare

Impact 5 million patient lives in FY22 by enabling access to more affordable healthcare solutions

Healthcare Spend

- 70% Spend for drugs
- 30% Spend for services & others

Traditional Pharma approach

Re-imagined Patient Ecosystem

Total G-CSF market volume (Europe)*

*Biosimilar introduced in Sep’08

*Includes filgrastim, pegfilgrastim and lenograstim
Targeting a financially attractive global market

EU has already witnessed strong adoption of biosimilars while the US market has recently started picking up driving future growth.

WW Biosimilars Market Size

Source: Management estimates based on originator company reported 2019 sales.
Developing ‘High Precision’ biosimilars at all scale

Very well positioned with FDA approval of Insulins, mABs & Therapeutic Proteins

- 2 R&D sites
- 890+ Patents granted*
- 28 Products in pipeline
- 7 Commercial Products

*Status Jun 2020

and over 100 other countries
# Focusing on high-value therapeutic areas

Broad portfolio with majority of 28 biosimilars to be launched in the next decade

<table>
<thead>
<tr>
<th>Therapeutic Areas</th>
<th>Molecule</th>
<th>Stage</th>
<th>Originator WW 2019 net sales ($ Bn)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Oncology</strong></td>
<td>Pegfilgrastim</td>
<td>Early Dev./ Preclinical</td>
<td>~20</td>
</tr>
<tr>
<td></td>
<td>Trastuzumab</td>
<td>Phase I</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Bevacizumab</td>
<td>Phase III</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Pertuzumab</td>
<td>Planned Sub. / Filed</td>
<td></td>
</tr>
<tr>
<td><strong>Immunology</strong></td>
<td>Adalimumab*</td>
<td>Approved / Marketed</td>
<td>~37</td>
</tr>
<tr>
<td></td>
<td>Etanercept*</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Undisclosed</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Diabetes</strong></td>
<td>Glargine** 100U</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Glargine 300U</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Aspart</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>RHI^^</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Undisclosed</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Ophthalmology</strong></td>
<td>Undisclosed</td>
<td></td>
<td>~8</td>
</tr>
<tr>
<td><strong>Bone Health</strong></td>
<td>Undisclosed</td>
<td></td>
<td>~5</td>
</tr>
</tbody>
</table>

*Partner Mylan has in-licensed product (Biocon benefits from economic interest); **Japan is outside of Mylan partnership; ^^RHI completed Ph1 and considering potential Ph-3 waiver to be confirmed with FDA advice, shown as Planned submission. **Note: Mylan is responsible for commercialisation of all the disclosed products mentioned above except RHI in US and EU.
Solid expertise in difficult-to-manufacture biologics

Understand the science, scale, scope & complexity of manufacturing biologics in a competitive cost structure

3 Manufacturing sites (2 Bangalore, 1 Malaysia) 25+ cGMP approvals (incl. FDA & EMA)

- Drug Substance, Drug Product & Device Capability
- Proprietary *P. pastoris* & mammalian CHO and NSO cell-based platform
- Large-scale capacity catering to global needs
- Robust regulatory compliance
Providing access to more affordable biosimilars in over 120 countries

On route to have increasing direct presence in key geographies

*Full legal entity registered but awaiting the CNPJ, the official identification numbers for companies
Enabling access and healthcare cost optimisation with non-traditional approaches

Global collaboration with Voluntis for development & distribution of a Digital Therapeutic for diabetics

Digitally-Enabled personalized insulin tomorrow

Insulin (Semglee) + Companion DTx (Insulia) = Optimised Therapy

Patient Healthcare Outcomes

Healthcare Costs
Targeting $1 billion revenue by FY22

Building ‘commercial’ band-width to continuously strengthen performance

Recent and Upcoming Launches

- **Semglee** 100 units/ml
- Bevacizumab & Aspart
- rH Insulin

Note: Mylan responsible for commercialization of Semglee, Fulphila and Ogivri in US and EU.

Improve Market Share in Developed Markets

- **Fulphila** ~16% of PFS market
- **Ogivri** Double-digit share in 9 markets
  #1 Biosimilar to Trastuzumab

Expand Presence in MoW Markets

- Most of World markets: 44% YoY growth in Q1’21
A vision driven by a strong belief that ‘healthcare is a human right’

Fully integrated global platform built on 40+ years of strong heritage

Operating in a sizeable global market with strong growth potential

Developing portfolio of 28 biosimilars across high-value therapeutic areas

Solid expertise in difficult-to-manufacture, large-scale, biologics

Commercial reach in 120+ countries with increasing direct presence

Highly experienced global management team setting out to achieve $1B by FY22

Biocon Biologics
Transforming Healthcare, Transforming Lives.